

Company Results Review

30 October 2006 | 7 pages

Oriental Bank of Commerce (ORBC.BO)

2Q07 Results: Asset Recoveries, but What About the Margin?

- Up 50%: And 50% ahead of our estimates: OBC has meaningfully beaten our estimates at the net profit level. Not so at the pre-provisioning ex-trading gains levels, where its 28% yoy growth is in-line with expectations. The strong outperformance is driven by large write-backs on the loan book; a positive and ahead of expectations.
- Write-backs: Continue, and are large OBC is delivering relatively belatedly on recoveries from GTB that it had acquired about 2 years ago. The trickle is becoming a flow, the numbers are large and even going forward, and the recoveries could be ahead of most estimates. A positive, for earnings, capital and management deliveries.
- But, low margins fall further, and disappoint OBC operates at among the lowest margins among peers; instead of normalizing, margins have dipped further. We believe this possibly reflects a modest funding franchise, aggressive asset growth, and poor management pricing. While base margins suggest more upside than risk, concrete measures are not in evidence yet.
- Maintain Hold/Medium Risk The stock's strong bounce-back, valuations inline with the market, the best likely on asset recoveries, and not enough apparent measures on margin revival, suggest modest stock performance rather than meaningful upside or downside movements ahead.

Hold/Medium Risk	2M
Price (30 Oct 06)	Rs259.65
Target price	Rs285.00
Expected share price return	9.8%
Expected dividend yield	1.7%
Expected total return	11.5%
Market Cap	Rs65,053M
	US\$1,444M

Price Performance (RIC: ORBC.BO, BB: OBC IN)							
INR							
260			^				
240	hand	\					
220	V ~ V	\					
200							
180		1. /					
160		M					
140		, V					
30 Dec	31 Mar	30 Jun	29 Sep				

Figure 1. Statistical Abstract									
Year to March	Net Profit (Rs Mils.)	FD EPS (Rs)	EPS Growth (%)	P/E (X)	P/BV (X)	ROAE (%)	ROAA (%)	Div Yld (%)	
FY05	7,608	39.5	10.9	6.6	2.1	30.3	1.6	1.2	
FY06	5,572	25.1	-36.4	10.3	1.5	16.4	1.0	1.7	
FY07E	5,947	23.7	-5.6	10.9	1.3	12.7	0.9	1.7	
FY08E	7,817	31.2	31.4	8.3	1.2	14.9	1.1	1.7	
FY09E	9,612	38.4	23.0	6.8	1.0	16.1	1.2	1.7	

Source: Company Reports and Citigroup Investment Research

Aditya Narain, CFA¹

+91-22-6631-9879 aditya.narain@citigroup.com

Manish Chowdhary¹

+91-22-6631-9853

manish.chowdhary@citigroup.com

Himani Shah1**

himani.shah@citigroup.com

See page 5 for Analyst Certification and important disclosures.

Citigroup Research is a division of Citigroup Global Markets Inc. (the "Firm"), which does and seeks to do business with companies covered in its research reports. As a result, investors should be aware that the Firm may have a conflict of interest that could affect the objectivity of this report. Investors should consider this report as only a single factor in making their investment decision. Non-US research analysts who have prepared this report, and who may be associated persons of the member or member organization, are not registered/qualified as research analysts with the NYSE and/or NASD, but instead have satisfied the registration/qualification requirements or other research-related standards of a non-US jurisdiction.

^{**}US investors please do not contact this analyst 1Citigroup Global Market India Private Limited

Fiscal year end 31-Mar	2005	2006	2007E	2008E	2009E
Valuation Ratios					
P/E (x)	6.6	10.3	10.9	8.3	6.8
P/E - reported (x)	6.6	10.3	10.9	8.3	6.8
P/BV (x)	2.1	1.5	1.3	1.2	1.0
P/Adjusted BV (x)	2.1	1.5	1.3	1.2	1.0
Dividend yield (%)	1.2	1.7	1.7	1.7	1.7
Per Share Data (Rs)					
EPS (adjusted)	39.51	25.15	23.74	31.20	38.36
EPS (reported)	39.51	25.15	23.74	31.20	38.36
BVPS	121.95	177.13	195.80	221.94	255.24
Tangible BVPS	121.95	177.13	195.80	221.94	255.24
Adjusted BVPS	121.95	177.13	195.80	221.94	255.24
DPS	3.00	4.50	4.50	4.50	4.50
Profit & Loss (RsM)					
Net interest income	15,237	16,051	17,033	19,938	23,046
Fees and commissions	1,565	2,043	2,452	2,820	3,243
Other operating Income	3,532	3,317	2,152	2,335	2,898
Total operating income	20,334	21,411	21,636	25,093	29,187
Total operating expenses	-7,957	-9,659	-10,893	-11,987	-13,412
Oper. profit bef. provisions	12,377	11,753	10,743	13,106	15,775
Bad debt provisions	-4,001	-3,598	302	-1,189	-1,294
Non-operating/exceptionals	-45	167	-2,550	-750	-750
Pre-tax profit	8,330	8,322	8,496	11,167	13,731
Tax	-722	-2,750	-2,549	-3,350	-4,119
Extraord./Min. Int./Pref. Div.	0	0	0	0	0
Attributable profit	7,608	5,572	5,947	7,817	9,612
Reported net income	7,608	5,572	5,947	7,817	9,612
Adjusted earnings	7,608	5,572	5,947	7,817	9,612
Growth Rates (%)					
EPS (adjusted)	10.9	-36.4	-5.6	31.4	23.0
Oper. profit bef. prov.	-19.5	-5.0	-8.6	22.0	20.4
Balance Sheet (RsM)					
Total assets	530,905	582,043	678,195	779,133	892,073
Avg Interest earning assets	474,159	557,539	625,970	720,298	823,223
Customer loans	275,915	356,876	428,327	509,662	592,634
Gross NPLs	25,128	21,163	17,826	18,888	21,165
Liab. & shar. funds	530,905	582,043	678,195	779,133	892,073
Total customer deposits	478,503	501,975	591,931	684,677	787,420
Reserve for loan losses	22,923	21,104	18,685	18,091	17,497
Shareholders' equity	23,480	44,378	49,056	55,605	63,948
Profitability/Solvency Ratios (%)					
ROE adjusted	30.3	16.4	12.7	14.9	16.1
Net interest margin	3.2	2.9	2.7	2.8	2.8
Cost/income ratio	39.1	45.1	50.3	47.8	46.0
Cash cost/average assets	1.7	1.7	1.7	1.6	1.6
NPLs/customer loans	9.1	5.9	4.2	3.7	3.6
Reserve for Ioan Iosses/NPLs	91.2	99.7	104.8	95.8	82.7
Bad debt prov./avg. cust. loans	1.6	1.1	-0.1	0.3	0.2
Loans/deposit ratio	57.7	71.1	72.4	74.4	75.3
Tier 1 capital ratio	6.1	11.7	10.7	10.2	10.1
Total capital ratio	9.8	12.5	11.8	11.1	10.9

For further data queries on Citigroup's full coverage universe please contact CIR Data Services Asia Pacific at +852-2501-2791.



	2Q07	2Q06	YoY %	1Q07	QoQ%	Citigroup Investment Research Comments
Interest Income	12,822	10,069	27.3	11,353	12.9	Bolstered by aggressive loan expansion
Interest Expense	(8,695)	(6,027)	44.3	-7,244	20.0	Aggressive, and apparently high cost, deposit expansion
Net Interest Income	4,128	4,042	2.1	4,110	0.4	Lower than expectation, reflecting a margin compression on already low margins
Fee-Based Income	1,380	747	84.8	1,211	14.0	Very strong gains; could well include some one-offs, clarity needed
Other Non-Interest Income	199	973	-79.6	476	-58.3	Sharp dip - relatively surprising in a favorable fixed income market
Non Interest Income	1,579	1,720	-8.2	1,687	-6.4	
Operating Income	5,707	5,762	-1.0	5,797	-1.5	
Operating Expenses	(2,566)	(2,503)	2.5	(2,287)	12.2	Key driver of operating profitability
Pre-Provision Profit	3,141	3,259	-3.6	3,510	-10.5	
Charges for Bad Debts	737	(324)	NM	648	13.8	Impressive write-backs on NPL's - consistent with previous quarter, and a little ahead of expectations
Other Operating Items		0	NM	(2,124)	NM	
Operating Profit	3,878	2,935	32.1	2,033	90.7	
Pre-Tax Profit	3,878	2,935	32.1	2,033	90.7	
Tax	(771)	(670)	15.1	(481)	60.3	
Extraordinary Items	(612)	(612)	0.0	(612)	0.0	
Net Profit	2,495	1,653	51.0	940	165.4	About 50% ahead of our expectations - driven entirely by loan book write-backs
EPS	9.96	7.44	33.8	3.75	165.4	
Customer Loans	386,501	300,416	28.7	364,494	6.0	Inline with industry growth
Customer Deposits	597,815	493,622	21.1	545,063	9.7	Aggressive deposit growth - well ahead of market expansion
AIEA	617,830	490,342	26.0	594,971	3.8	
AIBL	564,959	470,799	20.0	580,499	-2.7	
Total Assets	685,916	570,646	20.2	647,776	5.9	
Avg Assets	666,846	547,823	21.7	626,587	6.4	
Non-Performing Loans (NPL)	18,486	23,853	-22.5	20,450	-9.6	Asset quality performance has been impressive
Loan Loss Reserves (LLR)	(16,776)	(21,734)	-22.8	(18,840)	-11.0	
Shareholders' Funds	45,929	26,173	75.5	42,167	8.9	
Book Value Per Share	183	118	55.5	168	8.9	
Key Ratios (%)	2Q07		Bps ∆ YoY		$Bps \Delta QoQ$	Citigroup Investment Research Comments
ROAA (annualized)	1.46	1.16	30	0.58	87	
ROAE (annualized)	21.73	25.26	-353	8.92	1281	
Net Interest Margin (bps)	267	330	-62	276	-9	Key disappointment - well below industry margins get pushed even lower
Fee Inc/Operating Income	24.2	13.0	1123	20.9	330	Smart pickup, though clarity needed on composition
Other Non-Interest Inc/Op Inc	27.7	29.9	-218	29.1	-143	
Op. Cost/ Operating Income	45.0	43.4	152	39.4	551	Cost efficiencies fundamentally ahead of market; though current performance in line with industry
Loan-to-Deposit Ratio (LDR)	64.7	60.9	379	66.9	-222	Relatively greater funding flexibility than peers
NDL /L D - L' -	4.8	7.9	-316	5.61	-83	
NPL/Loan Ratio	7.0				-138	

Oriental Bank of Commerce Company Description

Oriental Bank of Commerce was established in 1943 and nationalized in the second round of nationalization in 1980. The bank is headquartered in Delhi, and the government holds 66% of the bank's equity. OBC is a medium-sized bank with a share of about 2% in deposits and advances of the Indian banking system. OBC has a domestic network of 1,100 branches and extension counters.

Investment Thesis

We rate OBC as a Hold/Medium Risk (2M) stock, with a target price of Rs285. OBC is a small North India-based government bank that has over the past few years aggressively cleaned up its balance sheet and lowered net NPLs to zero. In August 2004, OBC embarked on the takeover of Global Trust Bank, a failed private-sector bank based in Southern India, with a view to acquiring a branch network in that region. This has not worked out well, in our view. It was too expensive, integration has taken too much time, management has changed at OBC, and overall profitability has been hurt. This transaction has effectively pegged down OBC from being among the most profitable and expensive banks among government banks to one of the cheapest but least profitable banks in the system. Interest rates remain a risk. OBC's bond portfolio is among the most exposed to interest rates in the sector, in our view: high yield, high duration, and with limited accounting protection.

However, the basic business and franchise remains solid: the asset book is clean and OBC's geographic concentration in North India is an advantage. We believe the balance sheet and operating structure is lean enough to be aggressively turned around, supporting higher profitability and valuations. The stock has had a good run in the last couple of months and valuations no longer look cheap at 1.25x one-year forward BV.

Valuation

Our target price of Rs285 is based on our EVA methodology. We assume a risk-free rate of 8% and a beta of 1. Our loan loss expectation is 75bps, in line with the average for government banks. We are also benchmarking our target price against 1.3x one-year forward P/BV, which translates into a valuation of Rs272. Our target multiple continues to be at discounts to those for SBI, PNB and Corporation Bank. We believe a valuation discount to some peer banks is still justified due to the quality and structure of the businesses and given pressures on operating profitability, and franchise issues on the funding front. We prefer to use EVA as our primary methodology, as we believe it adjusts well for the relatively dynamic cost of capital and captures well the long-term value of the business.

Risks


We rate OBC as Medium Risk, as implied by our quantitative risk-rating system, which tracks 260-day share price volatility and based on its business profile. Its NPLs are low, operating profitability is high and management has some gains as a cushion for its bond portfolio. The risks to our target price for OBC lie in its relatively small size, new top management team, and more negative surprises from its recently consummated acquisition. The small size of the bank suggests that a few mistakes or individuals could hurt what we believe is a safe and high-quality balance sheet. In addition, a sharp increase in interest rates could erode the bond portfolio and raise deposit mobilization costs. The key upside risks to our target price include: (1) significant recoveries from the large NPL book it has recently acquired; (2) fall in interest rates, which would ease the pain from its bond book; and (3) pick-up in acquisition execution and effectiveness.

Analyst Certification Appendix A-1

We, Aditya Narain, CFA and Manish Chowdhary, research analysts and the authors of this report, hereby certify that all of the views expressed in this research report accurately reflect our personal views about any and all of the subject issuer(s) or securities. We also certify that no part of our compensation was, is, or will be directly or indirectly related to the specific recommendation(s) or view(s) in this report.

IMPORTANT DISCLOSURES

Oriental Bank of Commerce (ORBC.BO)



Citigroup Global Markets Inc. or its affiliates has received compensation for investment banking services provided within the past 12 months from Oriental Bank of Commerce.

Citigroup Global Markets Inc. or an affiliate received compensation for products and services other than investment banking services from Oriental Bank of Commerce in the past 12 months.

Citigroup Global Markets Inc. currently has, or had within the past 12 months, the following company(ies) as investment banking client(s): Oriental Bank of Commerce.

Citigroup Global Markets Inc. currently has, or had within the past 12 months, the following company(ies) as clients, and the services provided were non-investment-banking, securities-related: Oriental Bank of Commerce.

Citigroup Global Markets Inc. currently has, or had within the past 12 months, the following company(ies) as clients, and the services provided were non-investment-banking, non-securities-related: Oriental Bank of Commerce.

Analysts' compensation is determined based upon activities and services intended to benefit the investor clients of Citigroup Global Markets Inc. and its affiliates ("the Firm"). Like all Firm employees, analysts receive compensation that is impacted by overall firm profitability, which includes revenues from, among other business units, the Private Client Division, Institutional Sales and Trading, and Investment Banking.

For important disclosures (including copies of historical disclosures) regarding the companies that are the subject of this Citigroup Investment Research product ("the Product"), please contact Citigroup Investment Research, 388 Greenwich Street, 29th Floor, New York, NY, 10013, Attention: Legal/Compliance. In addition, the same important disclosures, with the exception of the Valuation and Risk assessments and historical disclosures, are contained on the Firm's disclosure website at www.citigroupgeo.com. Private Client Division clients should refer to www.smithbarney.com/research. Valuation and Risk assessments can be found in the text of the most recent research note/report regarding the subject company. Historical disclosures (for up to the past three years) will be provided upon request.

<u>·</u>			
Citigroup Investment Research Ratings Distribution			
Data current as of 30 September 2006	Buy	Hold	Sell
Citigroup Investment Research Global Fundamental Coverage (2914)	46%	40%	14%
% of companies in each rating category that are investment banking clients	44%	43%	32%
India Asia Pacific (105)	59%	16%	25%
% of companies in each rating category that are investment banking clients	52%	65%	38%

Guide to Fundamental Research Investment Ratings:

Citigroup Investment Research's stock recommendations include a risk rating and an investment rating.

Risk ratings, which take into account both price volatility and fundamental criteria, are: Low (L), Medium (M), High (H), and Speculative (S).

Investment ratings are a function of Citigroup Investment Research's expectation of total return (forecast price appreciation and dividend yield within the next 12 months) and risk rating.

For securities in emerging markets (Asia Pacific, Emerging Europe/Middle East/Africa, and Latin America), investment ratings are: Buy (1) (expected total return of 15% or more for Low-Risk stocks, 20% or more for Medium-Risk stocks, 30% or more for High-Risk stocks, and 40% or more for Speculative stocks); Hold (2) (5%-15% for Low-Risk stocks, 10%-20% for Medium-Risk stocks, 15%-30% for High-Risk stocks, and 20%-40% for Speculative stocks); and Sell (3) (5% or less for Low-Risk stocks, 10% or less for Medium-Risk stocks, 15% or less for High-Risk stocks, and 20% or less for Speculative stocks). Investment ratings are determined by the ranges described above at the time of initiation of coverage, a change in investment and/or risk rating, or a change in target price (subject to limited management discretion). At other times, the expected total returns may fall outside of these ranges because of market price movements and/or other short-term volatility or trading patterns. Such interim deviations from specified ranges will be permitted but will become subject to review by Research Management. Your decision to buy or sell a security should be based upon your personal investment objectives and should be made only after evaluating the stock's expected performance and risk.

OTHER DISCLOSURES

Citigroup Global Markets Inc. or its affiliates holds a long position in any class of common equity securities of Oriental Bank of Commerce.

For securities recommended in the Product in which the Firm is not a market maker, the Firm is a liquidity provider in the issuers' financial instruments and may act as principal in connection with such transactions. The Firm is a regular issuer of traded financial instruments linked to securities that may have been recommended in the Product. The Firm regularly trades in the securities of the subject company(ies) discussed in the Product. The Firm may engage in securities transactions in a manner inconsistent with the Product and, with respect to securities covered by the Product, will buy or sell from customers on a principal basis.

Securities recommended, offered, or sold by the Firm: (i) are not insured by the Federal Deposit Insurance Corporation; (ii) are not deposits or other obligations of any insured depository institution (including Citibank); and (iii) are subject to investment risks, including the possible loss of the principal amount invested. Although information has been obtained from and is based upon sources that the Firm believes to be reliable, we do not guarantee its accuracy and it may be incomplete and condensed. Note, however, that the Firm has taken all reasonable steps to determine the accuracy and completeness of the disclosures made in the Important Disclosures section of the Product. In producing Products, members of the Firm's research department may have received assistance from the subject company(ies) referred to in the Product. Any such assistance may have included access to sites owned, leased or otherwise operated or controlled by the issuers and meetings with management, employees or other parties associated with the subject company(ies). Firm policy prohibits research analysts from sending draft research to subject companies. However, it should be presumed that the author of the Product has had discussions with the subject company to ensure factual accuracy prior to publication. All opinions, projections and estimates constitute the judgment of the author as of the date of the Product and these, plus any other information contained in the Product, are subject to change without notice. Prices and availability of financial instruments also are subject to change without notice. Notwithstanding other departments within the Firm advising the companies discussed in this Product, information obtained in such role is not used in the preparation of the Product. Although Citigroup Investment Research does not set a predetermined frequency for publication, if the Product is a fundamental research report, it is the intention of Citigroup Investment Research to provide research coverage of the/those issuer(s) mentioned therein, including in response to news affecting this issuer, subject to applicable quiet periods and capacity constraints. The Product is for informational purposes only and is not intended as an offer or solicitation for the purchase or sale of a security. Any decision to purchase securities mentioned in the Product must take into account existing public information on such security or any registered prospectus.

Investing in non-U.S. securities, including ADRs, may entail certain risks. The securities of non-U.S. issuers may not be registered with, nor be subject to the reporting requirements of the U.S. Securities and Exchange Commission. There may be limited information available on foreign securities. Foreign companies are generally not subject to uniform audit and reporting standards, practices and requirements comparable to those in the U.S. Securities of some foreign companies may be less liquid and their prices more volatile than securities of comparable U.S. companies. In addition, exchange rate movements may have an adverse effect on the value of an investment in a foreign stock and its corresponding dividend payment for U.S. investors. Net dividends to ADR investors are estimated, using withholding tax rates conventions, deemed accurate, but investors are urged to consult their tax advisor for exact dividend computations. Investors who have received the Product from the Firm may be prohibited in certain states or other jurisdictions from purchasing securities mentioned in the Product from the Firm. Please ask your Financial Consultant for additional details. Citigroup Global Markets Inc. takes responsibility for the Product in the United States. Any orders by US investors resulting from the information contained in the Product may be placed only through Citigroup Global Markets Inc.

The Citigroup legal entity that takes responsibility for the production of the Product is the legal entity which the first named author is employed by. The Product is made available in Australia to wholesale clients through Citigroup Global Markets Australia Pty Ltd. (ABN 64 003 114 832 and AFSL No. 240992) and to retail clients through Citigroup Wealth Advisors Pty Ltd. (ABN 19 009 145 555 and AFSL No. 240813), Participants of the ASX Group and regulated by the Australian Securities & Investments Commission. Citigroup Centre, 2 Park Street, Sydney, NSW 2000. If the Product is being made available in certain provinces of Canada by Citigroup Global Markets (Canada) Inc. ("CGM Canada"), CGM Canada has approved the Product. Citigroup Place, 123 Front Street West, Suite 1100, Toronto, Ontario M5J 2M3. The Product may not be distributed to private clients in Germany. The Product is distributed in Germany by Citigroup Global Markets Deutschland AG & Co. KGaA, which is regulated by Bundesanstalt fuer Finanzdienstleistungsaufsicht (BaFin). Frankfurt am Main, Reuterweg 16, 60323 Frankfurt am Main. If the Product is made available in Hong Kong by, or on behalf of, Citigroup Global Markets Asia Ltd., it is attributable to Citigroup Global Markets Asia Ltd., Citibank Tower, Citibank Plaza, 3 Garden Road, Hong Kong. Citigroup Global Markets Asia Ltd. is regulated by Hong Kong Securities and Futures Commission. If the Product is made available in Hong Kong by The Citigroup Private Bank to its clients, it is attributable to Citibank N.A., Citibank Tower, Citibank Plaza, 3 Garden Road, Hong Kong. The Citigroup Private Bank and Citibank N.A. is regulated by the Hong Kong Monetary Authority. The Product is made available in India by Citigroup Global Markets India Private Limited, which is regulated by Securities and Exchange Board of India. Bakhtawar, Nariman Point, Mumbai 400-021. If the Product was prepared by Citigroup Investment Research and distributed in Japan by Nikko Citigroup Ltd., it is being so distributed under license. Nikko Citigroup Limited is regulated by Financial Services Agency, Securities and Exchange Surveillance Commission, Japan Securities Dealers Association, Tokyo Stock Exchange and Osaka Securities Exchange. Akasaka Park Building, 2-20, Akasaka 5-chome, Minato-ku, Tokyo 107-6122. The Product is made available in Korea by Citigroup Global Markets Korea Securities Ltd., which is regulated by Financial Supervisory Commission and the Financial Supervisory Service. Hungkuk Life Insurance Building, 226 Shinmunno 1-GA, Jongno-Gu, Seoul, 110-061. The Product is made available in Malaysia by Citigroup Global Markets Malaysia Sdn Bhd, which is regulated by Malaysia Securities Commission. Menara Citibank, 165 Jalan Ampang, Kuala Lumpur, 50450. The Product is made available in Mexico by Acciones y Valores Banamex, S.A. De C. V., Casa de Bolsa, which is regulated by Comision Nacional Bancaria y de Valores. Reforma 398, Col. Juarez, 06600 Mexico, D.F. In New Zealand the Product is made available through Citigroup Global Markets New Zealand Ltd., a Participant of the New Zealand Exchange Limited and regulated by the New Zealand Securities Commission. Level 19, Mobile on the Park, 157 lambton Quay, Wellington. The Product is made available in Poland by Dom Maklerski

Banku Handlowego SA an indirect subsidiary of Citigroup Inc., which is regulated by Komisja Papierów Wartosciowych i Gield. Bank Handlowy w Warszawie S.A. ul. Senatorska 16, 00-923 Warszawa. The Product is made available in the Russian Federation through ZAO Citibank, which is licensed to carry out banking activities in the Russian Federation in accordance with the general banking license issued by the Central Bank of the Russian Federation and brokerage activities in accordance with the license issued by the Federal Service for Financial Markets. Neither the Product nor any information contained in the Product shall be considered as advertising the securities mentioned in this report within the territory of the Russian Federation or outside the Russian Federation. The Product does not constitute an appraisal within the meaning of the Federal Law of the Russian Federation of 29 July 1998 No. 135-FZ (as amended) On Appraisal Activities in the Russian Federation, 8-10 Gasheka Street, 125047 Moscow. The Product is made available in Singapore through Citigroup Global Markets Singapore Pte, Ltd., a Capital Markets Services Licence holder, and regulated by Monetary Authority of Singapore. 1 Temasek Avenue, #39-02 Millenia Tower, Singapore 039192. Citigroup Global Markets (Pty) Ltd. is incorporated in the Republic of South Africa (company registration number 2000/025866/07) and its registered office is at 145 West Street, Sandton, 2196, Saxonwold. Citigroup Global Markets (Pty) Ltd. is regulated by JSE Securities Exchange South Africa, South African Reserve Bank and the Financial Services Board. The investments and services contained herein are not available to private customers in South Africa. The Product is made available in Taiwan through Citigroup Global Markets Inc. (Taipei Branch), which is regulated by Securities & Futures Bureau. No portion of the report may be reproduced or quoted in Taiwan by the press or any other person. No. 8 Manhattan Building, Hsin Yi Road, Section 5, Taipei 100, Taiwan. The Product is made available in Thailand through Citicorp Securities (Thailand) Ltd., which is regulated by the Securities and Exchange Commission of Thailand. 18/F, 22/F and 29/F, 82 North Sathorn Road, Silom, Bangrak, Bangkok 10500, Thailand. The Product is made available in United Kingdom by Citigroup Global Markets Limited, which is authorised and regulated by Financial Services Authority. This material may relate to investments or services of a person outside of the UK or to other matters which are not regulated by the FSA and further details as to where this may be the case are available upon request in respect of this material. Citigroup Centre, Canada Square, Canary Wharf, London, E14 5LB. The Product is made available in United States by Citigroup Global Markets Inc, which is regulated by NASD, NYSE and the US Securities and Exchange Commission. 388 Greenwich Street, New York, NY 10013. Unless specified to the contrary, within EU Member States, the Product is made available by Citigroup Global Markets Limited, which is regulated by Financial Services Authority. Many European regulators require that a firm must establish, implement and make available a policy for managing conflicts of interest arising as a result of publication or distribution of investment research. The policy applicable to Citigroup Investment Research's Products can be found at www.citigroupgeo.com. Compensation of equity research analysts is determined by equity research management and Citigroup's senior management and is not linked to specific transactions or recommendations. The Product may have been distributed simultaneously, in multiple formats, to the Firm's worldwide institutional and retail customers. The Product is not to be construed as providing investment services in any jurisdiction where the provision of such services would be illegal. Subject to the nature and contents of the Product, the investments described therein are subject to fluctuations in price and/or value and investors may get back less than originally invested. Certain high-volatility investments can be subject to sudden and large falls in value that could equal or exceed the amount invested. Certain investments contained in the Product may have tax implications for private customers whereby levels and basis of taxation may be subject to change. If in doubt, investors should seek advice from a tax adviser. Advice in the Product has been prepared without taking account of the objectives, financial situation or needs of any particular investor. Accordingly, investors should, before acting on the advice, consider the appropriateness of the advice, having regard to their objectives, financial situation and needs.

© 2006 Citigroup Global Markets Inc. Citigroup Investment Research is a division and service mark of Citigroup Global Markets Inc. and its affiliates and is used and registered throughout the world. Citigroup and the Umbrella Device are trademarks and service marks of Citigroup or its affiliates and are used and registered throughout the world. Nikko is a registered trademark of Nikko Cordial Corporation. All rights reserved. Any unauthorized use, duplication, redistribution or disclosure is prohibited by law and will result in prosecution. The information contained in the Product is intended solely for the recipient and may not be further distributed by the recipient. The Firm accepts no liability whatsoever for the actions of third parties. The Product may provide the addresses of, or contain hyperlinks to, websites. Except to the extent to which the Product refers to website material of the Firm, the Firm has not reviewed the linked site. Equally, except to the extent to which the Product refers to website material of the Firm takes no responsibility for, and makes no representations or warranties whatsoever as to, the data and information contained therein. Such address or hyperlink (including addresses or hyperlinks to website material of the Firm) is provided solely for your convenience and information and the content of the linked site does not in anyway form part of this document. Accessing such website or following such link through the Product or the website of the Firm shall be at your own risk and the Firm shall have no liability arising out of, or in connection with, any such referenced website.

ADDITIONAL INFORMATION IS AVAILABLE UPON REQUEST